For information on this past event please contact Meetings Management

Provisional Conference Program

Wednesday 13th September 2006


SESSION 5:
ANTIGENS, EPITOPES & DENDRITIC CELLS
Moderator: Eszter Nagy (Intercell AG, Vienna, Austria)

08.30-09.00
‘ISCOMATRIX® vaccines target and facilitate cross-presentation in dendritic cells in vivo
Nick Wilson et al. (CSL Limited, Parkville, Victoria, Australia)

09.00-09.20
‘Multiple-TLR activation by heat-killed Brucella abortus (HKBA): a potent adjuvant for preventive and therapeutic vaccines’
Hana Golding et al. (CBER, FDA, Bethesda, Maryland, USA)

09.20-09.40
‘The identification of a novel surface protein from Campylobacter jejuni - A potential vaccine candidate for the treatment of bacterial gastroenteritis’
Petra Schrotz-King et al. (ACE Biosciences, Odense, Denmark)

09.40-10.00
‘NS1 non-structural protein of tick-borne encephalitis virus - protective immunity in experimental animal models, elicited by different delivery systems’
A.V. Timofeev and J.R. Stephenson (Engelhardt Institute of Molecular Biology, Moscow, Russia)

10.00-10.20
‘Induction of CTL responses against the protozoan parasite Theileria parva by heterologous prime-boost and dendritic cell vaccination’
Simon P. Graham et al. (International Livestock Research Institute, Nairobi, Kenya)

10.20-10.40
‘Penetratin linked to proteins or peptides induce cellular and protective immune responses via diverse processing mechanisms’
Dodie S. Pouniotis (Burnet Institute, Heidelberg, Victoria, Australia)

10.40-11.00
Coffee & Posters

SESSION 6:
PARTICULATE DELIVERY SYSTEMS
Moderator: Russell J. Mumper (University of Kentucky, Lexington, Kentucky, USA)

11.00-11.20
‘Pharmaceutically engineered nanoparticles as delivery systems for HIV-1 protein-based vaccines: In vitro and in vivo evaluation’
Russell J. Mumper, Jigna Patel, Siva Gandhapudi, David Galey, Julia Jones, Jerold Woodward and Avi Nath (University of Kentucky, Lexington, Kentucky, USA)

11.20-11.40
‘Development of single-shot vaccines based on modified dextran technology’
Bas H.A. Kremer et al. (OctoPlus Technologies BV, Leiden, The Netherlands)

11.40-12.00
‘Surfactant free colloidal poly(DL-lactic acid) (PLA) particles: a potent adjuvant’
Thierry Delair et al. (CNRS-Biomerieux, Lyon, France)

12.00-12.20
‘Virus-like particles as a customisable vaccine’
M. Peacey, M. Baird and V. Ward (University of Otago, Dunedin, New Zealand)

12.20-12.40
‘Positive results of BioVant calcium phosphate (CaP) adjuvant study with H5N1 avian flu antigen’
P. Nagappan, A. Mitchell, S. Billingsley and S.J.D. Bell (BioSante Pharmaceuticals Inc., Smyrna, Georgia, USA)

12.40-13.00
‘Lyophilization of the cationic liposomal adjuvant based on DDA and TDB’
Dennis Christensen et al. (Statens Serum Institut, Copenhagen, Denmark)

13.00-14.00
Lunch & Posters

SESSION 7:
DNA VACCINES
Moderator: Jedd Wolchok (MSKCC, New York, USA)

14.00-14.30
‘CpG DNA interferes with negative selection of developing B cells and stimulates autoantibody production’
Doron Melamed (Technion, Haifa, Israel)

14.30-15.00
‘Impact of RNA- and codon optimization on safety and efficacy of HIV specific DNA vaccines’
Ralf Wagner (GENEART GmbH, Regensburg, Germany)

15.00-15.20
‘Evaluation of DNA vaccines for biodefense applications: Electroporation enhanced immunization against anthrax toxin subunits’
Alain Luxembourg (Ichor Medical Systems Inc, San Diego, USA)

15.20-15.40
‘Design, selection and optimisation of an influenza pDNA vaccine formulation’
Mary K. Wloch et al. (VICAL Inc., San Diego, USA)

15.40-16.00
Tea & Posters

16.00-16.20
‘DERMAVIR: Dendritic cell-based topical immunization for the treatment of HIV/AIDS’
Julianna Lisiewicz (Genetic Immunity, Budapest, Hungary/Washington DC, USA)

16.20-16.40
‘DNA vaccines for autoimmune disease:results from a phase I/II clinical trial of a DNA plasmid (BHT-3009) for multiple sclerosis and pre-clinical results of a DNA plasmid (BHT-3021) for type I diabetes’
Hideki Garren (Bayhill Therapeutics inc., Palo Alto, California, USA)

16.40-17.00
’Comparison of a bacteriophage-delivered and a commercially available hepatitis B vaccine’
John B. March, Jason R. Clark and Kath Thomas (Moredun Research Institute, Edinburgh, UK)

17.00-17.20
‘Harnessing dendritic cells and TLR ligands to enhance the immunogenicity of a plasmid DNA/MVA prime boost vaccine against SIV in Rhesus Macaques’
Marcin Kwissa et al. (Emory Vaccine Center, Atlanta, Georgia, USA)

SESSION 8:
DNA VACCINES - ELECTROPORATION
Moderator: Jedd Wolchok (MSKCC, New York, USA)

17.20-17.50
‘Enhancing DNA vaccine delivery with electroporation: Considerations for clinical implementation’
Drew Hannaman (Ichor Medical Systems Inc, San Diego, USA)

17.50-18.10
‘Electroporation-assisted intramuscular delivery of plasmid DNA vaccines: Evaluation of immunogenicity, plasmid DNA persistence and integration’
Mary K. Wloch et al. (VICAL Inc., San Diego, USA)

18.10-18.30
‘HIV and smallpox DNA vaccine efficacy is enhanced using a novel constant-current electroporation delivery system in non-human primates’
Amir S. Khan et al. (ADViSYS Inc., The Woodlands, Texas, USA)

18.30-18.50
‘DNA delivered by electrical pulses; human clinical trials’
Torunn E. Tjelle et al. (Inovio Biomedical Corporation, San Diego, California, USA)

Free Evening for Delegates